
StudyFinder
Cardiac Sarcoidosis Randomized Trial

RECRUITING
18 years and over
Inclusion Criteria:
(i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:
* advanced conduction system disease (defined as Mobitz II AV block or third degree AV block)
* significant sinus node dysfunction (defined as average HR less than 40bpm when awake and/or sustained atrial arrhythmias)
* non- sustained or sustained ventricular arrhythmia
* left ventricular dysfunction (LVEF \< 50%)
* right ventricular dysfunction (RVEF \< 40%)
AND
(ii) No alternative explanation for clinical features
AND
(iii) Nuclear Imaging within six-months of enrollment consisting of FDG-PET scan with FDG uptake suggestive of active CS and myocardial perfusion imaging
AND ONE OR BOTH OF FOLLOWING
(iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac)
(v) CT Chest showing features consistent with pulmonary sarcoidosis and/or mediastinal and/or hilar lymphadenopathy
Exclusion Criteria:
• Current or recent (within two months) non-topical treatment for sarcoidosis
• Current Oral/IV treatment of duration greater than 5 days
• Currently taking Methotrexate or Prednisone for another health condition
• Intolerance or contra-indication to Methotrexate or Prednisone
• Patient does not meet all of the above listed inclusion criteria
• Patient is unable or unwilling to provide informed consent
• Patient is included in another randomized clinical trial
• Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe claustrophobia
• Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrollment)
• Breastfeeding
• Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study
• Patients for whom the investigator believes that the trial is not in the interest of the patient
DRUG: Prednisone or Prednisolone, DRUG: Methotrexate
Cardiac Sarcoidosis, Sarcoidosis
Cardiac Sarcoidosis, Prednisone (or Prednisolone), Methotrexate
David H Birnie, MD - dbirnie@ottawaheart.ca
Kron, Jordana
PHASE3
HM20014180
NCT03593759
See this study on ClinicalTrials.gov